The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
12
Quintiles, Inc.
Overland Park, Kansas, United States
Tolerability
Safety and tolerability of RNS60 administered by IV infusion to healthy volunteers.
Time frame: 6 days
Biomarkers
Analysis of blood samples for various biomarkers
Time frame: 6 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.